<DOC>
	<DOCNO>NCT01363895</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) common sustain cardiac arrhythmia , associate increase risk morbidity mortality1 . The management AF patient aim reduce symptom prevent severe complication associate AF . In last year , two new strategy emerge different objective . In PROTECT AF study2 , percutaneous closure Left Atrial Appendage ( LAA ) closure device provide alternative strategy oral anticoagulation stroke prophylaxis . The AFFIRM trial3 show drug-based management AF rhythm-control strategy confer advantage rate-control strategy cardiovascular mortality might associate increased noncardiovascular death rate4 . Catheter ablation gain great place rhythm control strategy , show superiority maintain sinus rhythm comparison AAD5 . However , persistent AF , repeat ablation procedure necessary 70 % patient achieve sinus rhythm long-term follow-up6-7 . This prospective , randomized trial compare percutaneous closure LAA combine rate-control strategy catheter ablation management patient persistent AF . Patients eligible catheter ablation well LAA closure device implantation willing participate study randomly assign catheter ablation percutaneous closure LAA closure device implantation relation 1:1 . The primary endpoint study composite endpoint 12 month cause death , thrombo-embolic event , major bleeding ( BARC type 3 ) , re-hospitalisation severe symptom due arrhythmias . Secondary endpoint include composite endpoint bleeding , composite endpoint thrombo-embolic event , cardio-vascular mortality , total duration hospitalisation , sustain discontinue anticoagulation , quality life improvement , use Antiarrhythmic Drugs ( AAD ) , total cost , freedom arrhythmia average ventricular frequency 7-day holter ECG 12 month . The objective study assess superiority percutaneous closure LAA combine rate-control catheter ablation patient oligosymptomatic AF .</brief_summary>
	<brief_title>Interventional Strategies Treatment Atrial Fibrillation : Percutaneous Closure Left Atrial Appendage Versus Catheter Ablation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Patients oligosymptomatic AF eligible intervention ( CA LAA closure device implantation ) . 2 . Written , inform consent patient her/his legallyauthorized representative participation study . 3 . In woman childbearing potential negative pregnancy test mandatory . 1 . Left atrial thrombus 2 . Other indication AF oral anticoagulation ( valve prosthesis , pulmonary embolism , recurrent vein thrombosis ) 3 . Contraindication oral anticoagulation 4 . Severe valvular heart disease 5 . Severe leave ventricular systolic function ( ejection fraction &lt; 30 % ) 6 . Malignancies comorbid condition ( example severe liver , renal pancreatic disease ) life expectancy le 12 month may result protocol noncompliance . 7 . Pregnancy ( present , suspected plan ) positive pregnancy test . 8 . Patient 's inability fully cooperate study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>catheter ablation</keyword>
	<keyword>percutaneous closure LAA</keyword>
	<keyword>intervention</keyword>
</DOC>